Clinical trial · Interventional
OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer
A Phase II Randomized Study of OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer (NSCLC)
NCT00230126CI-TRIAL-00030900completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study determines tumor response rate, time to tumor progression and survival rate at 1 year produced by OSI-774 in previously treated African American patients with nonsmall cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Non-Small-Cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| erlotinib | Drug | Erlotinib | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- A erlotinib 150 mg
- description
- erlotinib 150 mg/day cycles 1 - 3
- interventionNames
- Drug: erlotinib
- type
- EXPERIMENTAL
- label
- B erlotinib modified according to weight
- description
- erlotinib Cycle 1 dose modified according to patient's weight; Cycles 2 and up, dose titrated to skin rash.
- interventionNames
- Drug: erlotinib
Primary outcomes (3)
- measure
- Disease Control Rate at 12 Weeks
- timeFrame
- 12 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Must have histologically or cytologically confirmed stage IIIB or IV NSCLC treated with 1-2 platinum- or taxane-containing regimens * Measurable disease * May have had prior surgery \& external beam radiation * African American * 18 years or older Exclusion Criteria: * Known brain mets * Prior treatment with EGFR targeting therapies * Pregnant/lactating women
References
Publications (0)
Data not yet available
No reference posted for this study.